Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination

被引:77
作者
Castanheira, Mariana [1 ]
Deshpande, Lalitagauri M. [1 ]
Messer, Shawn A. [1 ]
Rhomberg, Paul R. [1 ]
Pfaller, Michael A. [1 ]
机构
[1] JMI Labs, Beaver Kreek Ctr 345, North Liberty, IA 52317 USA
关键词
Azoles; Yeast; Resistance mechanism; Candida tropicalis; Candida parapsilosis; Antifungal susceptibility testing; FLUCONAZOLE RESISTANCE; ECHINOCANDIN RESISTANCE; FKS MUTATIONS; CHANGING EPIDEMIOLOGY; MOLECULAR-MECHANISMS; SUSCEPTIBILITY; IDENTIFICATION; INFECTIONS; COLLECTION; EMERGENCE;
D O I
10.1016/j.ijantimicag.2019.09.003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study evaluated the activity of echinocandins, azoles and amphotericin B against Candida spp. isolates and other yeasts and characterised azole resistance mechanisms in Candida parapsilosis and Candida tropicalis. Invasive Candida spp. isolates (n = 2936) collected in 60 hospitals worldwide during 20162017 underwent antifungal susceptibility testing by broth microdilution. Azole-resistant C. parapsilosis and C. tropicalis were submitted to qPCR for ERG11, CDR1 and MDR1, and the whole genome sequence was analysed. Results of non-susceptibility to echinocandins ranged from 0.0-2.3%, being highest in Candida glabrata. More than 99.0% of the Candida albicans isolates were susceptible to both fluconazole and voriconazole. Fluconazole resistance in C. glabrata was 6.5% overall, being highest in the USA (13.0%). Resistance to voriconazole in Candida krusei was only noted in the USA (5.0%). Azoles inhibited 89.1-91.6% of C. parapsilosis isolates, with most resistant isolates noted in Europe (15.1%), including 36 isolates from Italy (three hospitals), of which 34 harboured Erg11 Y132F mutations and overexpressed MDR1. Azole non-wild-type C. tropicalis (7/227) were found in five countries: 3 isolates from Thailand had the same Erg11 Y132F alteration. Fluconazole non-wild-type isolates were noted among 3/77 (3.9%) Candida dubliniensis, 4/17 (23.5%) Candida guilliermondii, 4/47 (8.5%) Candida lusitaniae and other less common yeast species. Echinocandin use has been recommended over fluconazole for invasive Candida infections. However, azoles are still active against the most common Candida spp. and resistance appears to be restricted to certain geographic regions and associated with Erg11 Y132 alterations in C. parapsilosis and C. tropicalis. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页数:10
相关论文
共 39 条
  • [1] Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
    Alexander, Barbara D.
    Johnson, Melissa D.
    Pfeiffer, Christopher D.
    Jimenez-Ortigosa, Cristina
    Catania, Jelena
    Booker, Rachel
    Castanheira, Mariana
    Messer, Shawn A.
    Perlin, David S.
    Pfaller, Michael A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 56 (12) : 1724 - 1732
  • [2] [Anonymous], 2016, M59 CLSI
  • [3] Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
    Arendrup, Maiken Cavling
    Patterson, Thomas F.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S445 - S451
  • [4] Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern
    Astvad, K. M. T.
    Johansen, H. K.
    Roder, B. L.
    Rosenvinge, F. S.
    Knudsen, J. D.
    Lemming, L.
    Schonheyder, H. C.
    Hare, R. K.
    Kristensen, L.
    Nielsen, L.
    Gertsen, J. B.
    Dzajic, E.
    Pedersen, M.
    Ostergard, C.
    Olesen, B.
    Sondergaard, T. S.
    Arendrup, M. C.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2018, 56 (04)
  • [5] The current treatment landscape: candidiasis
    Bassetti, Matteo
    Peghin, Maddalena
    Timsit, Jean-Francois
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 : 13 - 22
  • [6] Fluconazole resistance in Candida species: a current perspective
    Berkow, Elizabeth L.
    Lockhart, Shawn R.
    [J]. INFECTION AND DRUG RESISTANCE, 2017, 10 : 237 - 245
  • [7] Castanheira M, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00906-17, 10.1128/aac.00906-17]
  • [8] Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013)
    Castanheira, Mariana
    Messer, Shawn A.
    Rhomberg, Paul R.
    Pfaller, Michael A.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2016, 85 (02) : 200 - 204
  • [9] Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates
    Castanheira, Mariana
    Woosley, Leah N.
    Messer, Shawn A.
    Diekema, Daniel J.
    Jones, Ronald N.
    Pfaller, Michael A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 577 - 580
  • [10] Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs
    Castanheira, Mariana
    Woosley, Leah N.
    Diekema, Daniel J.
    Jones, Ronald N.
    Pfaller, Michael A.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (01) : 117 - 124